Welcome

Initial Targeted Indications

Indication	Targeted Subgroup	Formulation	Unique selling point (USP)
Body Sculpting	Double chin	Injectable	Significantly less inflammation than currently marketed injectable; Single treatment efficacy expected to be sufficient in majority of clients
	Central abdominal bulge	Injectable	No available injectable
Dupuytren’s Disease	Progressive contractures post hand surgery or Xiaflex injection(s)	Injectable sustained release	Large unmet medical need for effective disease modifying treatment
	Progressive contractures post hand surgery or Xiaflex injection(s)	Topical	Large market for effective treatment that can be patient-administered

Indication	Targeted Subgroup	Formulation	Unique selling point (USP)
Uncontrolled Type 2 diabetes mellitus (T2DM)	Overweight and requiring insulin	Injectable	Unique short term treatment reduces body weight and improves glycemic control and reduces cardiovascular risk (CV) factors
NASH	Obese with metabolic syndrome	Injectable / Oral	Improvement in liver parameters, including fibrosis and significant reduction in CV risk factors